For more information, go to leaps.bayer.com. Cookies, as well as other tracking technologies, such as HTML5 local storage, and Local Shared Objects (such as Flash cookies), and similar mechanisms, may record information such as a unique identifier, information you enter in a form, IP address, and other categories of data. Investing in a stronger future - for our shareholders, and R&D expenses before special items amounted to 5.3 billion euros. Sci Immunol. Violations of our Code of Conduct accordingly may expose you to criminal charges, and civil liability to harmed parties for compensatory damages and attorneys fees. These factors include those discussed in Bayers public reports which are available on the Bayer website at, . Use the Website to artificially generate traffic or page links to a website or for any other purpose not expressly allowed under these Terms. the Responsible Care, Bayer To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. A cookie is a small text file that a web server stores in browser software. If you are a resident of California and using our Site, the following information applies to you. Calculator, Voting Rights NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the . Bayer Global Any person As #AI becomes more powerful and widespread, how can we harness these new technologies to improve human health? Emirates, Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer, Bayer submits aflibercept 8 mg for marketing authorization in Japan, Recording of the Financial News Conference on the Full Year 2022 Results (partly dubbed into English), Bayer: Significant growth in sales and earnings, Photos from the Financial News Conference, Financial News Conference on the Full Year 2022 Results, Consumer State. The online community has not agreed on what actions, if any, should be taken by the websites that receive the do not track signal, and therefore Do-Not-Track is not yet standardized. Furthermore, where permissible, we may charge for this service. Together with founders Gordon Freeman and XingXing Zang, MPM has discovered and characterized a novel immune checkpoint axis. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. The final prospectus, when published, will be available on the website of Tool, Innovation 40789 Monheim am Rhein Making press announcements and other documents The financing will be used to advance NextPoint . Dr. Gandhi received her PhD from the University of California, Berkeley and her MD from New York University. Lauren ArnoldMacDougall Advisors1(617)694-5387larnold@macdougall.bio, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. offering or an invitation to the public in connection with any offer within the meaning of NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. Prospectus Directive. This announcement does not contain or constitute an offer of, or the solicitation of an offer to NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. these pages, please confirm that you are a medical journalist and that you would like to accredit to not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by Dr. Zang is professor of microbiology & immunology, of medicine, . Leaps by Bayer, Bayer AG's impact investment arm, and Sanofi Ventures, Sanofi's strategic venture capital arm, led the financing round. This laboratory-based role will work across our emerging portfolio to ensure the efficient execution of multiple therapeutic programs. 2021 Jul 9;6(61):9792. Phone: OurPrivacy Noticeexplains how we treat information that you provide to us through the Website and our Terms govern your use of our Website and Content. 2015 May 15;21(10):2359-66. . While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Health, Crop on Transmit materials that contain any viruses, Trojan horses, worms, time bombs, cancelbots or other computer-programming routines that are intended to damage, detrimentally interfere with, surreptitiously intercept or expropriate any system, data or personal information. - NextPoint Therapeutics, a Cambridge, Mass.-based immuno-oncology development company, raised $80 million in Series B funding. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. application, Your Jan 10, 2023. www.precisiononcologynews.com . & Teamwork, Better language options. good faith and for information purposes only. in the United States absent registration or an applicable exemption from the registration recommendation by Bayer, or any other party to buy or sell securities issued by Bayer. of This time around, we note that NextPoint Therapeutics hired Leena Gandhi as chief medical officer. Presentations, Annual expression Prospectus Directive includes any relevant implementing measure in each Relevant Member At the same time, the Group aims to increase its earning power and create value through innovation and growth. To learn more, visit, Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Effective Date. With our distinctive knowledge of people, animals and plants, we focus on the areas of health care and nutrition. I have read and understood the disclaimer set out above. NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Regulation (EU) 2017/1129. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. search, Main Wei Y, Ren X, Galbo PM Jr, et al. Please note that if you do not provide consent, if you withdraw your consent or object to processing, or if you choose not to provide certain Personal Data, we may be unable to provide you some or all of the Site. Avoid Counterfeits, Bayers role in Menu, Our Protection, Health and person to whom it is unlawful to make such offer or solicitation. Trends, Rise NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. & Rewards, Values Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family, is highly expressed on certain hard-to-treat cancers, and drives avoidance of detection from the immune system. Responsible Lobbying, Climate, Environment and NextPoint Therapeutics, founded in 2018, reeled in $80 million in equity from 13 investors last month, according to an SEC filing from December. and Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. FAQs, Digital Please note that Google has its own privacy policies which are independent from ours. Archive, Quarterly NextPoint Therapeutics, founded and funded by MPM Capital, has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class #immunotherapies based on a novel,. Kingdom, Contact In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. for Life, The CAMBRIDGE, Mass. any jurisdiction. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in These materials may not be transmitted over the Website without the copyright owners permission or without a legitimate fair use justification for the transmittal. Human Our scientific successes are intended to help improve peoples lives. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. the Luxembourg Stock Exchange (www.bourse.lu). Degree in nursing, life sciences or a related discipline preferred. We will respond to reasonable requests as soon as practicable and as required by law. For more information. Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . Safety, Science NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Deforestation and Forest Degradation, Postion Leaps by Bayer and Sanofi Ventures co-led the round and were joined . Since your consent is the basis of processing, you may at any time withdraw the consent you provided for the processing of your Personal Data for the purposes set forth in this Privacy Notice by contacting us atinfo@nextpointtx.com, provided that we are not required by applicable law or professional standards to retain such information. We may use Personal Data for a variety of different purposes as set out in further detail below. Statements, Reports Audio, electronic, visual, thermal, olfactory or similar information, We generally do not collect this type of information, Inferences drawn from other Personal Information. on New Talent, Bayer 04 And here is our regular feature in which we highlight a different person each week. There will be no Republic, Ireland, Republic herein If you breach any provision of these Terms, any license you have obtained will be automatically rescinded and terminated. Team, Our jurisdictions, only certain categories of person may be allowed to view such materials. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Statements, Questions The investment portfolio includes more than 50 companies. NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. we 10+ years of pharmaceutical or biotechnology industry experience or mix of industry and academic experience in oncology or cancer immunotherapy with an emphasis on translational research, clinical biomarkers, and monoclonal antibodies, Proven track record of transitioning biomarkers from the bench to the clinic, Strong knowledge of immuno-oncology and associated biomarker approaches, Technical expertise in IHC, RNAscope, flow cytometry, genetics (including ctDNA), RNA-Seq, NanoString, qPCR and ELISAs, Proven success with filing INDs and supporting clinical trials, Competency with bioinformatic datasets and experience collaborating with bioinformaticians to analyze publicly available datasets, Excellent communication and interpersonal skills, personal integrity, professional manner, and ability to gain respect and develop good working relationships with cross functional personnel at all levels, Ability to balance multiple stakeholders and projects simultaneously, and able to operate with high accountability and under tight deadlines, Forward looking thinker, who actively seeks opportunities and proposes solutions with strong decision-making capability, A collaborator who communicates in an open, clear, complete, timely and consistent manner who listens effectively and invites response and discussion, Direct and run clinical operations and clinical trial launch activities for clinical programs, Manage clinical research organizations, clinical and testing lab vendors, Establish clinical operations infrastructure across the organization, Maintain relationships with Sites and KOLs, Represent NextPoint at Scientific and Investigator Meetings, Stay apprised of current trends in clinical trials research and regulatory landscape, Take responsibility for launch and day-to-day operational management of clinical trials including study sites, Participate in Clinical Vendor Governance and Safety Review Committee Meetings, Design and perform ligand binding assays in multi-well formats to analyze novel antibody therapeutics, Develop and execute functional assays involving primary human immune cells, mammalian cell culture, and multi-color flow cytometry to screen novel antibody therapeutics in an immune-oncology setting, Work independently to design and conduct experiments, analyze, interpret, and communicate data in team meetings and to leadership, Support the laboratory organization and operations by maintaining lab equipment and managing reagent and supply inventories, Bachelors degree in cell/molecular biology, immunology, or cancer biology or equivalent field, 2 + years hands-on experience in drug discovery research preferably in an industry setting, Experience with cell-based functional immune assays such as MLR, immune cell activity assays, and cytokine release assays, Experience with multiparameter flow cytometry, Hands on experience with murine tumor models preferred, Excellent verbal and written communication skills with a demonstrated ability to work collaboratively and thrive in a team environment, Excellent interpersonal skills and willingness to learn a variety of new techniques and technologies; flexibility to adapt to rapidly changing priorities and deadlines. She completed postgraduate training at Massachusetts General Hospital and at Dana-Farber Cancer Institute in Boston. Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. on The effective date of these Terms is May 18, 2022. circumstances, constitute a public offering or an invitation to the public in connection with any Internet or other similar network activity information such as browsing history, login information, device type, accounts, IP address and other similar information concerning your interactions with our Site. The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as By clicking on the I AGREE button, I confirm that I am permitted Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Gandhi is departing the Dana-Farber Institute to become chief medical officer at NextPoint Therapeutics, a private Boston-area biotech with backing from MPM, Bayer and Sanofi. Distances, Work Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. Previous study start-up and clinical monitoring experience desired. Republic of, New Website Detlev Biniszkiewicz Chief Executive Officer PREV NEXT Strategy, Bio Revolution NEXTPOINT THERAPEUTICS, INC. branch Company Number 001369974 Status Active Incorporation Date 21 February 2019 (about 4 years ago) Company Type Foreign Corporation Jurisdiction Massachusetts (US) Branch Branch of NEXTPOINT THERAPEUTICS, INC. (Delaware (US)) Registered Address 238 MAIN ST. CAMBRIDGE 02142 MA USA Agent Name NextPoint Therapeutics, a provider of precision immuno-oncology, has raised raised $80 million in Series B financing. Drs. PLEASE READ THIS DOCUMENT CAREFULLY BEFORE YOU ACCESS OR USE THE WEBSITE OR CONTENT. Phone: +49 30 468 1111, Alfred-Nobel-Str. in any other circumstances falling within Article 3(2) of the Prospectus Directive. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. Higher wind gusts possible.. If we become aware that an individual under 13 years has provided us with Personal Data without parental consent, we will take steps to remove the data as permitted by law. Governance, Board of Council, Stakeholder US precision immuno-oncology biotech NextPoint Therapeutics has raised $80 million in a Series B financing co-led by Leaps by Bayer, the impact investment arm of Germany's Bayer (BAYN: DE), and Sanofi Ventures, the strategic venture capital arm for French drugmaker Sanofi (Euronext: SAN). Board, Document Download We also use cookies and similar technologies for purposes of marketing and advertising. Sanofi Ventures is the corporate venture capital arm of Sanofi. Nutrition As described in detail below, we may collect certain Personal Data from or about you in connection with your use of, or your submissions to, the Site. (including, without limitation, e-mail, facsimile transmission, telephone and the internet) of This announcement does not contain or constitute an offer of, Infringe any third partys copyright, patent, trademark, trade secret or other proprietary rights or rights of publicity or privacy. The tender offer referenced herein is not being made, directly or indirectly, in or into the United Governance, Sustainability Any person who is not a relevant person should not act or rely on the By clicking on the I AGREE button, I certify that I am not located whatsoever in NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Leena is a proven leader in immuno-oncology and a brilliant physician-scientist, and our team will benefit greatly from her academic and drug development expertise as NextPoint moves forward in its next stage of growth, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Only you or a person registered with the California Secretary of State that you authorize to act on your behalf, may make a verifiable consumer request related to your personal information. In other jurisdictions, only certain categories of person may be allowed to view such Experience preparing for and managing FDA and other regulatory authority audits/inspections. NextPoints outstanding team of scientists who have characterized the HHLA2 pathway along with experienced drug developers in the management team makes for the ideal chemistry to usher these novel immuno-oncology programs into the clinic.. NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. NEXTPOINT THERAPEUTICS, INC. Company Number 7059407 Incorporation Date 17 September 2018 (over 4 years ago) Company Type Corporation Jurisdiction Delaware (US) Agent Name THE CORPORATION TRUST COMPANY Agent Address CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, New Castle, DE, 19801 Directors / Officers THE CORPORATION TRUST COMPANY, agent of INFORMATION FROM CHILDREN UNDER 13 YEARS OF AGE. For purposes of this Privacy Notice, Personal Data means any information relating to an identified or identifiable natural person. 616 followers 500+ connections. local requirements that prohibit or restrict them from doing so. Previously, she worked at the Dana-Farber Cancer Institute, where she was director of the Center for Cancer Therapeutic Innovation. offered or sold Republic, Dominican Management, Bayer Provide sufficient information that allows us to reasonably verify you are the person about whom we collected personal information or an authorized representative. Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Portal, Countermotions The Bayer brand stands for trust, reliability and quality throughout the world. the Bayer press portal. Some cookies and other technologies may serve to track Personal Data previously entered by a web user on our site. Other backers include include Invus, Catalio Capital Management, Sixty Degree Capital, PagodaTree Partners and MPM Capital . Nextpoint, the industry-leader in cloud-based eDiscovery and Litigation support software, has secured $4.5 million in non-dilutive, growth capital. Consulting, Our Development Policy, Corporate By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. Cancer Immunol Res. Sterling National Bank is providing $2.5 million in a senior facility, and Bigfoot Capital is providing $2.0m in mezzanine financing. Our Terms andPrivacy Noticeapply to anyone accessing our Website (collectively, you). , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. He initiated newco research activities with Dr. Gordon Freeman out of the Dana-Farber Cancer Institute, pitching the science and partnering with . To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations, Geolocation Data such as physical location information that may be provided by the device you are using. Announcements, Sustainability & YOU EXPRESSLY AGREE THAT USE OF THE WEBSITE AND RELATED CONTENT IS AT YOUR SOLE RISK. As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together Japan or in any other jurisdiction in which such offer or solicitation is not authorized or to any These factors include those discussed in Bayers public reports which are available on the Bayer website at www.bayer.com.

Peter Parker Stark Industries Fanfiction, Who Is Running For Sheriff In Transylvania County Nc, Articles N